More Vaccine Disappointment For Sanofi As First C Diff Toxoid Vaccine Fails
Executive Summary
A second dose of bad news for Sanofi's vaccines unit sees its C. difficile vaccine dropped after a Phase III study was deemed unlikely to succeed.
You may also be interested in...
Pfizer Holds Out Hope For C. Diff Vaccine Despite Clinical, Commercial Failures
Pfizer’s Clostridioides difficile vaccine candidate missed a Phase III primary endpoint but the company may seek a path forward based on secondary endpoints even after past failures in the field.
Synthetic Biologics’ Ribaxamase Setback Shows Difficulty Of C. Difficile Development
Company believes there is a path forward for developing ribaxamase in Phase III, based on discussions with the FDA, but deaths in Phase II meant loss of breakthrough designation.
Sanofi Underpins Vaccine Strategy With New Manufacturing Facilities
Sanofi's major investments in vaccine manufacturing are continuing with the expansion of its Toronto, Canada facility, to be completed in 2021.